Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuichi Ando

Showing results (11-20 of 241) with videos related to

Pageof 25
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2022
[Chemotherapy for Older Patients with Cancer]Ayako Mitsuma, Yuichi Ando
Lung Cancer (Amsterdam, Netherlands)|November 3, 2023
Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trialSatoshi Furune, Yuichi Ando
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 16, 2017
[Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)]Ayumu Matsuoka, Yuichi Ando
The New England Journal of Medicine|October 5, 2018
Cabozantinib in Hepatocellular CarcinomaOsamu Maeda, Yuichi Ando
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
FDA Approval Summary: Sonidegib-LetterBishal Gyawali, Yuichi Ando
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|February 9, 2013
[Genetic backgrounds of peripheral neuropathy induced by oxaliplatin]Ayako Mitsuma, Yuichi Ando
Rinsho Byori. the Japanese Journal of Clinical Pathology|November 24, 2015
[UGT1A1 Genotyping for Proper Use of Irinotecan]Ayumu Matsuoka, Yuichi Ando
The New England Journal of Medicine|May 3, 2002
Irinotecan in small-cell lung cancerYuichi Ando, William D Figg
The New England Journal of Medicine|February 4, 2016
Nivolumab in Nonsquamous Non-Small-Cell Lung CancerBishal Gyawali, Akiko Ota, Yuichi Ando
The Lancet. Oncology|October 5, 2015
Discordance between the results and conclusions of ICON7Bishal Gyawali, Tomoya Shimokata, Yuichi Ando
Pageof 25

Showing results (11-20 of 241) with videos related to

Sort By:
Pageof 25
Gan to Kagaku Ryoho. Cancer & Chemotherapy|January 20, 2022
[Chemotherapy for Older Patients with Cancer]Ayako Mitsuma, Yuichi Ando
Lung Cancer (Amsterdam, Netherlands)|November 3, 2023
Comment on: Carboplatin and irinotecan (CI) vs. Carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trialSatoshi Furune, Yuichi Ando
Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 16, 2017
[Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)]Ayumu Matsuoka, Yuichi Ando
The New England Journal of Medicine|October 5, 2018
Cabozantinib in Hepatocellular CarcinomaOsamu Maeda, Yuichi Ando
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2017
FDA Approval Summary: Sonidegib-LetterBishal Gyawali, Yuichi Ando
Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica|February 9, 2013
[Genetic backgrounds of peripheral neuropathy induced by oxaliplatin]Ayako Mitsuma, Yuichi Ando
Rinsho Byori. the Japanese Journal of Clinical Pathology|November 24, 2015
[UGT1A1 Genotyping for Proper Use of Irinotecan]Ayumu Matsuoka, Yuichi Ando
The New England Journal of Medicine|May 3, 2002
Irinotecan in small-cell lung cancerYuichi Ando, William D Figg
The New England Journal of Medicine|February 4, 2016
Nivolumab in Nonsquamous Non-Small-Cell Lung CancerBishal Gyawali, Akiko Ota, Yuichi Ando
The Lancet. Oncology|October 5, 2015
Discordance between the results and conclusions of ICON7Bishal Gyawali, Tomoya Shimokata, Yuichi Ando
Pageof 25